Revia

BMI >27 kg/m2, Pruritus, Disease + 9 more

Treatment

5 FDA approvals

20 Active Studies for Revia

Treatment for

BMI >27 kg/m2

What is Revia

NaltrexoneThe Generic name of this drug

Treatment SummaryNaltrexone is a drug derived from noroxymorphone and is used to block the effects of narcotics and alcohol. It is more potent and longer lasting than naloxone, which makes it a good treatment for heroin addiction. Naltrexone has been approved by the FDA to treat alcohol dependence.

Naltrexone Hydrochlorideis the brand name

image of different drug pills on a surface

Revia Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Naltrexone Hydrochloride

Naltrexone

1998

59

Approved as Treatment by the FDA

Naltrexone, otherwise known as Naltrexone Hydrochloride, is approved by the FDA for 5 uses including Alcoholism and Opioid Dependence .

Alcoholism

Helps manage Alcohol Dependency

Opioid Dependence

Helps manage Opioid Dependence

Pain

Used to treat Severe Pain in combination with Morphine

Therapeutic procedure

Used to treat inadequate alternative treatment options in combination with Morphine

Opiate Substitution Treatment

Used to treat requiring long-term opioid treatment in combination with Morphine

Effectiveness

How Revia Affects PatientsNaltrexone is a drug that blocks the effects of opioids in the body and is used to treat alcohol dependence. It stops the body from feeling the effects of opioids taken externally and blocks physical dependence on them. When taken with opioids, it can cause withdrawal symptoms in those who are physically dependent on them.

How Revia works in the bodyNaltrexone is a drug that blocks the effects of opioids in the brain. It does this by attaching itself to opioid receptors, which prevents other molecules, like endorphins, from binding to them. This stops the effects opioids have on the body, like pain relief, miosis, and respiratory depression. The major metabolite of naltrexone, 6-β-naltrexol, also has opioid blocking activity. It is unclear how it works to help treat alcoholism.

When to interrupt dosage

The serving of Revia is contingent upon the diagnosed problem, including Opioid Dependence, a reduced-calorie diet, and BMI >27 kg/m2. The measure of dosage diverges as per the method of delivery shown in the accompanying table.

Condition

Dosage

Administration

Therapeutic procedure

9.6 mg, 3.6 mg, 1.2 mg, 7.2 mg, 2.4 mg, 4.8 mg, , 50.0 mg, 3.2 mg, 2.0 mg, 4.0 mg, 90.0 mg, 380.0 mg/mL, 0.8 mg, 8.0 mg, 380.0 mg, 200.0 mg

Tablet, extended release, , Capsule, extended release - Oral, Injection, powder, for suspension, extended release; Kit, Tablet, film coated, Tablet, film coated, extended release, Tablet, extended release - Oral, Capsule, extended release, Oral, Kit - Intramuscular, Tablet, film coated, extended release - Oral, Subcutaneous, Tablet - Oral, Intramuscular, Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Tablet, Implant - Subcutaneous, Tablet, film coated - Oral, Implant

Disease

9.6 mg, 3.6 mg, 1.2 mg, 7.2 mg, 2.4 mg, 4.8 mg, , 50.0 mg, 3.2 mg, 2.0 mg, 4.0 mg, 90.0 mg, 380.0 mg/mL, 0.8 mg, 8.0 mg, 380.0 mg, 200.0 mg

Tablet, extended release, , Capsule, extended release - Oral, Injection, powder, for suspension, extended release; Kit, Tablet, film coated, Tablet, film coated, extended release, Tablet, extended release - Oral, Capsule, extended release, Oral, Kit - Intramuscular, Tablet, film coated, extended release - Oral, Subcutaneous, Tablet - Oral, Intramuscular, Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Tablet, Implant - Subcutaneous, Tablet, film coated - Oral, Implant

Alcoholism

9.6 mg, 3.6 mg, 1.2 mg, 7.2 mg, 2.4 mg, 4.8 mg, , 50.0 mg, 3.2 mg, 2.0 mg, 4.0 mg, 90.0 mg, 380.0 mg/mL, 0.8 mg, 8.0 mg, 380.0 mg, 200.0 mg

Tablet, extended release, , Capsule, extended release - Oral, Injection, powder, for suspension, extended release; Kit, Tablet, film coated, Tablet, film coated, extended release, Tablet, extended release - Oral, Capsule, extended release, Oral, Kit - Intramuscular, Tablet, film coated, extended release - Oral, Subcutaneous, Tablet - Oral, Intramuscular, Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Tablet, Implant - Subcutaneous, Tablet, film coated - Oral, Implant

Chronic Weight Management

9.6 mg, 3.6 mg, 1.2 mg, 7.2 mg, 2.4 mg, 4.8 mg, , 50.0 mg, 3.2 mg, 2.0 mg, 4.0 mg, 90.0 mg, 380.0 mg/mL, 0.8 mg, 8.0 mg, 380.0 mg, 200.0 mg

Tablet, extended release, , Capsule, extended release - Oral, Injection, powder, for suspension, extended release; Kit, Tablet, film coated, Tablet, film coated, extended release, Tablet, extended release - Oral, Capsule, extended release, Oral, Kit - Intramuscular, Tablet, film coated, extended release - Oral, Subcutaneous, Tablet - Oral, Intramuscular, Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Tablet, Implant - Subcutaneous, Tablet, film coated - Oral, Implant

increased physical activity

9.6 mg, 3.6 mg, 1.2 mg, 7.2 mg, 2.4 mg, 4.8 mg, , 50.0 mg, 3.2 mg, 2.0 mg, 4.0 mg, 90.0 mg, 380.0 mg/mL, 0.8 mg, 8.0 mg, 380.0 mg, 200.0 mg

Tablet, extended release, , Capsule, extended release - Oral, Injection, powder, for suspension, extended release; Kit, Tablet, film coated, Tablet, film coated, extended release, Tablet, extended release - Oral, Capsule, extended release, Oral, Kit - Intramuscular, Tablet, film coated, extended release - Oral, Subcutaneous, Tablet - Oral, Intramuscular, Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Tablet, Implant - Subcutaneous, Tablet, film coated - Oral, Implant

BMI >27 kg/m2

9.6 mg, 3.6 mg, 1.2 mg, 7.2 mg, 2.4 mg, 4.8 mg, , 50.0 mg, 3.2 mg, 2.0 mg, 4.0 mg, 90.0 mg, 380.0 mg/mL, 0.8 mg, 8.0 mg, 380.0 mg, 200.0 mg

Tablet, extended release, , Capsule, extended release - Oral, Injection, powder, for suspension, extended release; Kit, Tablet, film coated, Tablet, film coated, extended release, Tablet, extended release - Oral, Capsule, extended release, Oral, Kit - Intramuscular, Tablet, film coated, extended release - Oral, Subcutaneous, Tablet - Oral, Intramuscular, Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Tablet, Implant - Subcutaneous, Tablet, film coated - Oral, Implant

Pruritus

9.6 mg, 3.6 mg, 1.2 mg, 7.2 mg, 2.4 mg, 4.8 mg, , 50.0 mg, 3.2 mg, 2.0 mg, 4.0 mg, 90.0 mg, 380.0 mg/mL, 0.8 mg, 8.0 mg, 380.0 mg, 200.0 mg

Tablet, extended release, , Capsule, extended release - Oral, Injection, powder, for suspension, extended release; Kit, Tablet, film coated, Tablet, film coated, extended release, Tablet, extended release - Oral, Capsule, extended release, Oral, Kit - Intramuscular, Tablet, film coated, extended release - Oral, Subcutaneous, Tablet - Oral, Intramuscular, Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Tablet, Implant - Subcutaneous, Tablet, film coated - Oral, Implant

Opioid Dependence

9.6 mg, 3.6 mg, 1.2 mg, 7.2 mg, 2.4 mg, 4.8 mg, , 50.0 mg, 3.2 mg, 2.0 mg, 4.0 mg, 90.0 mg, 380.0 mg/mL, 0.8 mg, 8.0 mg, 380.0 mg, 200.0 mg

Tablet, extended release, , Capsule, extended release - Oral, Injection, powder, for suspension, extended release; Kit, Tablet, film coated, Tablet, film coated, extended release, Tablet, extended release - Oral, Capsule, extended release, Oral, Kit - Intramuscular, Tablet, film coated, extended release - Oral, Subcutaneous, Tablet - Oral, Intramuscular, Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Tablet, Implant - Subcutaneous, Tablet, film coated - Oral, Implant

reduced-calorie diet

9.6 mg, 3.6 mg, 1.2 mg, 7.2 mg, 2.4 mg, 4.8 mg, , 50.0 mg, 3.2 mg, 2.0 mg, 4.0 mg, 90.0 mg, 380.0 mg/mL, 0.8 mg, 8.0 mg, 380.0 mg, 200.0 mg

Tablet, extended release, , Capsule, extended release - Oral, Injection, powder, for suspension, extended release; Kit, Tablet, film coated, Tablet, film coated, extended release, Tablet, extended release - Oral, Capsule, extended release, Oral, Kit - Intramuscular, Tablet, film coated, extended release - Oral, Subcutaneous, Tablet - Oral, Intramuscular, Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Tablet, Implant - Subcutaneous, Tablet, film coated - Oral, Implant

Opiate Substitution Treatment

9.6 mg, 3.6 mg, 1.2 mg, 7.2 mg, 2.4 mg, 4.8 mg, , 50.0 mg, 3.2 mg, 2.0 mg, 4.0 mg, 90.0 mg, 380.0 mg/mL, 0.8 mg, 8.0 mg, 380.0 mg, 200.0 mg

Tablet, extended release, , Capsule, extended release - Oral, Injection, powder, for suspension, extended release; Kit, Tablet, film coated, Tablet, film coated, extended release, Tablet, extended release - Oral, Capsule, extended release, Oral, Kit - Intramuscular, Tablet, film coated, extended release - Oral, Subcutaneous, Tablet - Oral, Intramuscular, Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Tablet, Implant - Subcutaneous, Tablet, film coated - Oral, Implant

Comorbidity

9.6 mg, 3.6 mg, 1.2 mg, 7.2 mg, 2.4 mg, 4.8 mg, , 50.0 mg, 3.2 mg, 2.0 mg, 4.0 mg, 90.0 mg, 380.0 mg/mL, 0.8 mg, 8.0 mg, 380.0 mg, 200.0 mg

Tablet, extended release, , Capsule, extended release - Oral, Injection, powder, for suspension, extended release; Kit, Tablet, film coated, Tablet, film coated, extended release, Tablet, extended release - Oral, Capsule, extended release, Oral, Kit - Intramuscular, Tablet, film coated, extended release - Oral, Subcutaneous, Tablet - Oral, Intramuscular, Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Tablet, Implant - Subcutaneous, Tablet, film coated - Oral, Implant

Pain

9.6 mg, 3.6 mg, 1.2 mg, 7.2 mg, 2.4 mg, 4.8 mg, , 50.0 mg, 3.2 mg, 2.0 mg, 4.0 mg, 90.0 mg, 380.0 mg/mL, 0.8 mg, 8.0 mg, 380.0 mg, 200.0 mg

Tablet, extended release, , Capsule, extended release - Oral, Injection, powder, for suspension, extended release; Kit, Tablet, film coated, Tablet, film coated, extended release, Tablet, extended release - Oral, Capsule, extended release, Oral, Kit - Intramuscular, Tablet, film coated, extended release - Oral, Subcutaneous, Tablet - Oral, Intramuscular, Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Tablet, Implant - Subcutaneous, Tablet, film coated - Oral, Implant

Warnings

Revia Contraindications

Condition

Risk Level

Notes

Toxoplasma Infections

Do Not Combine

Withdrawal syndrome

Do Not Combine

Adrenal gland hypofunction

Do Not Combine

Toxoplasma Infections

Do Not Combine

There are 20 known major drug interactions with Revia.

Common Revia Drug Interactions

Drug Name

Risk Level

Description

Eluxadoline

Major

The risk or severity of constipation can be increased when Naltrexone is combined with Eluxadoline.

Methylene blue

Major

Naltrexone may increase the serotonergic activities of Methylene blue.

Methylnaltrexone

Major

Naltrexone may increase the opioid antagonism activities of Methylnaltrexone.

Naloxegol

Major

Naltrexone may increase the opioid antagonism activities of Naloxegol.

Acamprosate

Minor

The bioavailability of Acamprosate can be increased when combined with Naltrexone.

Revia Toxicity & Overdose RiskAnimals have a toxic dose of naltrexone between 1100-1550mg/kg for mice, 1450mg/kg for rats, and 1490mg/kg for guinea pigs. Taking very high doses of naltrexone (generally more than 1000mg/kg) can cause drooling, reduced energy levels, tremors, and seizures.

image of a doctor in a lab doing drug, clinical research

Revia Novel Uses: Which Conditions Have a Clinical Trial Featuring Revia?

Currently, 30 active studies are being conducted to assess the effectiveness of Revia in conjunction with a reduced-calorie diet, Pruritus alleviation and increased physical activity.

Condition

Clinical Trials

Trial Phases

reduced-calorie diet

0 Actively Recruiting

Pruritus

0 Actively Recruiting

increased physical activity

0 Actively Recruiting

Comorbidity

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

Pain

0 Actively Recruiting

Disease

0 Actively Recruiting

Opiate Substitution Treatment

0 Actively Recruiting

Alcoholism

7 Actively Recruiting

Phase 3, Not Applicable

Opioid Dependence

14 Actively Recruiting

Phase 3, Phase 4, Not Applicable, Phase 2, Phase 1, Early Phase 1

Chronic Weight Management

0 Actively Recruiting

BMI >27 kg/m2

0 Actively Recruiting

Revia Reviews: What are patients saying about Revia?

5Patient Review

2/21/2014

Revia for Prevention of Opiate Drug Abuse

I'm so glad I found this medication! It's been a month and it's working great for me with no side effects. I was using opiates and heroin before, but this pill has been a miracle for me.

5Patient Review

3/23/2009

Revia for Prevention of Opiate Drug Abuse

5Patient Review

1/11/2010

Revia for Prevention of Opiate Drug Abuse

I would like to learn more about this medication.

4.7Patient Review

1/13/2010

Revia for Habit of Drinking Too Much Alcohol

My fiance was an opiate addict for 3 years. He went to rehab and they gave him revia, which caused withdrawal symptoms for the first few days. But he tough it out and now he's been clean for a year! He's made so much progress and is the man I fell in love with again.

4.7Patient Review

5/13/2009

Revia for Prevention of Opiate Drug Abuse

I felt pretty bad after taking this, with diarrhea and still feeling cravings for Lortab.

4.3Patient Review

4/19/2015

Revia for Habit of Drinking Too Much Alcohol

Don't give up on this medication! It really does work, but it may take some time to see results.

4Patient Review

3/20/2011

Revia for Habit of Drinking Too Much Alcohol

I have never tried this treatment before.

3Patient Review

5/13/2011

Revia for Habit of Drinking Too Much Alcohol

I've only taken this medication twice, but I was very nauseous afterwards both times. The second time, I didn't even have dinner because the nausea was so severe. Finally threw up before going to bed. while this pill does seem to be effective as an appetite suppressant, the side effects are not worth it in my opinion.

3Patient Review

8/8/2008

Revia for Habit of Drinking Too Much Alcohol

2.7Patient Review

10/26/2013

Revia for Prevention of Opiate Drug Abuse

I'm not sure what to make of this treatment yet. I only just started taking it last night, so it's too early to tell if it's working or not. They prescribed it to me for cravings, and so far I haven't had any pain medication in 30 days.

1.3Patient Review

8/4/2011

Revia for Prevention of Opiate Drug Abuse

I was given this medication to help with cravings, and I'm now two months clean. However, the side effects were really bad. I constantly felt nauseous, my jaw was clenched all the time, I had headaches and chest pain. Additionally, I lost my appetite and just generally felt sick. I don't think I'll be taking this medication anymore.

1Patient Review

2/22/2016

Revia for Habit of Drinking Too Much Alcohol

I'm about to start this table, but I have an alcohol problem. Are there any other people out there taking it for alcohol?

1Patient Review

8/2/2008

Revia for Prevention of Opiate Drug Abuse

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about revia

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between ReVia and Vivitrol?

"The only form of naltrexone that is FDA-approved for treating opioid use disorder is the injectable form, Vivitrol. Naltrexone in any form will block the effects of opioid drugs. Taking naltrexone reduces your tolerance to opioids."

Answered by AI

What is the meaning of ReVia?

"This drug blocks the action of opiates, which are drugs used to treat pain. It may be used to treat intravenous opiate addiction or alcohol dependence."

Answered by AI

How does naltrexone make you feel?

"Naltrexone works by blocking the parts of the brain that are associated with pleasure from alcohol and drugs. By doing this, it makes it easier to stop drinking."

Answered by AI

How do you use ReVia?

"This medicine is taken by mouth, with or without food. The usual dose is 50 mg per day. You may be monitored by a health care professional when taking this medicine."

Answered by AI

Clinical Trials for Revia

Image of Behavioral Pharmacology Research Unit in Baltimore, United States.

Suvorexant (20mg/day)for Opioid Use Disorder

This trial studies if a drug may reduce cravings & pleasure from other drugs, helping people reduce their use.

No Cost For Treatment

Behavioral Pharmacology Research UnitJustin Strickland, PhD

Image of Bicycle Health in Boston, United States.

Traditional Induction Armfor Opioid Use Disorder

This trial will compare two methods of transitioning patients off opioids to buprenorphine/naloxone with the goal of finding a safer and more effective way.

Waitlist Available

Bicycle HealthScott Weiner, MD, MPHBicycle Health

Image of Stanford University in Stanford, United States.

Dose Escalation Levelfor Chronic Pancreatitis

This trial tests an epilepsy drug to see if it can reduce pain when used along with opioids to treat chronic abdominal pain in CP patients. Safety & tolerability will assess if it works.

Stanford University (+4 Sites)Aynur Unalp-Arida, MD, PhD

Image of University of British Columbia - Okanagan Campus in Kelowna, Canada.

Psilocybin-assisted Psychotherapyfor Chronic Pain

Kelowna, Canada

This trial tests if a type of psychedelic therapy can help people reduce their opioid use for chronic pain. Participation lasts 8 months and includes two 25mg psilocybin therapy sessions. Outcomes will be tracked for safety & effectiveness.

Waitlist Available

University of British Columbia - Okanagan CampusW. Francois Louw, MD

Have you considered Revia clinical trials? We made a collection of clinical trials featuring Revia, we think they might fit your search criteria.

Explore trials for Revia

Image of The University of Texas Health Science Center at Houston in Houston, United States.

Assertive Outreachfor Opioid Use Disorder

This trial is testing a new program to help youths with opioid use disorder in Houston. The program includes medication, counseling, and peer support. The goal is to see if this program can help engage and retain more people in treatment.

FDA Approved Drug

The University of Texas Health Science Center at HoustonJames R Langabeer, PhD

Image of Online Recruitment in Burlington, United States.

DynamiCare Motivation Support Programfor Alcoholism

This trial will test whether DynamiCare's program, which combines coaching with financial incentives, is more effective than usual care in reducing alcohol use among adult Medicaid recipients.

Waitlist Available

Online Recruitment (+1 Sites)Eric E Gastfriend, MBADynamiCare Health

Image of West Haven VA Healthcare System in West Haven, United States.

Pain Coping Skills Trainingfor Chronic Pain

This trial will evaluate if pain coping skills training and buprenorphine can help manage pain and reduce opioid use in patients with chronic pain who are receiving maintenance hemodialysis for end-stage renal disease.

Waitlist Available

FDA Approved Drug

West Haven VA Healthcare System (+15 Sites)Laura Dember, MD

Image of University of Delaware in Newark, United States.

MABCfor Opioid Addiction

This trial will study if the mABC Intervention, adapted for use with peripartum mothers receiving medication-assisted treatment for opioid use disorder, is more effective than a control intervention in improving parenting and infant outcomes.

University of DelawareMary Dozier, Ph.D.

Have you considered Revia clinical trials? We made a collection of clinical trials featuring Revia, we think they might fit your search criteria.

Explore trials for Revia

Image of Providence VA Medical Center, Providence, RI in Providence, United States.

STMSfor Opioid Addiction

This trial will test if a non-invasive brain stimulation technique is safe and tolerable for people with cocaine, opioid, or alcohol addiction.

Providence VA Medical Center, Providence, RIJohn E McGeary, PhD

Image of Behavioral Pharmacology Research Unit in Baltimore, United States.

Bridge Devicefor Opioid Use Disorder

This trial is designed to study the efficacy of the Bridge Device, a neuromodulator medical device, for the treatment of Opioid Use Disorder. The device was cleared by the FDA based on safety, but not efficacy. The trial will enroll persons with active OUD who will be randomly assigned to one of three conditions: active BD with placebo, sham BD with lofexidine, or sham BD and placebo. The study will monitor participants for withdrawal symptoms and tolerance after device removal.

FDA Approved Drug

Behavioral Pharmacology Research UnitEric Strain

Image of Wake Forest School of Medicine in Winston-Salem, United States.

Real TBS To The VmPFCfor Alcoholism

Winston-Salem, NC

This trial will test if transcranial magnetic stimulation can help people with alcohol use disorder abstain from drinking.

1 Prior Treatment

Wake Forest School of MedicineMerideth A Addicott, PhD

Image of The Mind Research Network in Albuquerque, United States.

Cognitive-Behavior Therapyfor Alcoholism

Albuquerque, NM

This trial will help researchers understand how changes in brain function relate to someone reducing their alcohol use.

Waitlist Available

The Mind Research Network (+1 Sites)Barbara McCrady, PhD

Have you considered Revia clinical trials? We made a collection of clinical trials featuring Revia, we think they might fit your search criteria.

Explore trials for Revia

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.

Back to top

Terms of Service Privacy Policy Security